Arcus Overhauls Cancer Development Strategy After Trial Setback, Focuses on Kidney Medication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy GILD?
Source: Benzinga
Discontinuation of STAR-221 Study: Arcus Biosciences has halted the Phase 3 STAR-221 study in collaboration with Gilead Sciences due to futility, as the combination treatment did not show improved overall survival compared to the standard therapy.
Impact on Stock Performance: Following the announcement, Arcus Biosciences' stock (RCUS) fell by 11.10%, reflecting investor concerns over the study's results and future prospects.
Focus on Casdatifan: Arcus will shift its research and development efforts towards casdatifan, a promising HIF-2α inhibitor, which has shown strong efficacy in late-line clear cell renal cell carcinoma patients.
Advancements in Oncology and I&I Pipelines: The company is also progressing with quemliclustat for pancreatic cancer and plans to introduce new oral small-molecule candidates targeting inflammatory conditions by 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 134.250
Low
105.00
Averages
137.88
High
154.00
Current: 134.250
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galapagos Enters Binding Agreement with Gilead for Acquisition
- Acquisition Agreement Details: Under the binding framework agreement with Gilead, Galapagos will receive 50% of the total acquisition consideration, amounting to $1.675 billion in upfront payments and any contingent milestone payments, highlighting its strategic significance in the biotech sector.
- Flexible Capital Utilization: The agreement allows Galapagos to deploy at least $500 million of its cash independently, including up to $150 million for share buybacks, enhancing its capital management flexibility and market confidence.
- Intellectual Property Licensing: The framework includes licenses for certain intellectual property rights related to Ouro's research programs, enabling Galapagos to acquire nearly all of Ouro's operational assets, thereby enriching its product pipeline, particularly in autoimmune disease projects.
- Potential Milestone Earnings: Galapagos is eligible for up to $100 million in milestone payments upon Gilead's initiation of registrational trials for gamgertamig, and will receive tiered royalties of 20-23% on net sales post-commercialization, indicating significant future revenue growth potential.
See More
Galapagos Enters Binding Agreement with Gilead for Ouro Medicines Acquisition
- Acquisition Agreement Details: Galapagos NV has entered into a binding agreement with Gilead Sciences, which will acquire all equity interests of Ouro Medicines for $1.675 billion, allowing Galapagos to secure 50% of the upfront consideration and milestone payments, ensuring sufficient funds for future strategic transactions.
- Product Development Progress: Gamgertamig, a clinical-stage T cell engager, has received Fast Track and Orphan Drug Designation from the FDA and is expected to enter registrational studies by 2027, highlighting its potential in treating autoimmune diseases.
- Cost Sharing Arrangement: Under the agreement, Galapagos will bear all pre-registration development costs for Gamgertamig, including Ouro's clinical trials, while registration-enabling clinical development costs will be shared equally, ensuring effective resource utilization.
- Commercialization Revenue: Gilead will be responsible for the global commercialization of Gamgertamig, with Galapagos entitled to tiered royalties of 20-23% on net sales, which is expected to generate substantial long-term revenue and enhance its market position.
See More
Entergy Partners with Meta, Stock Surges Over 8%
- Entergy Stock Surge: Entergy's stock jumped over 8% after announcing a partnership with Meta, which is expected to save Louisiana customers approximately $2 billion over 20 years, significantly enhancing the company's competitive position in the energy market.
- Carnival Lowers Profit Guidance: Carnival revised its full-year adjusted profit forecast down to about $2.21 per share from $2.48, resulting in a more than 3% drop in its stock price and causing peers like Norwegian Cruise Line and Royal Caribbean to experience similar declines.
- Meta Stock Decline: Meta's shares fell over 3% due to losing two pivotal court cases and announcing layoffs, leading to an 11% drop over the week, highlighting the legal and operational challenges the company is currently facing.
- Argan Exceeds Earnings Expectations: Argan reported fourth-quarter earnings of $3.47 per share on revenue of $262.1 million, surpassing analyst expectations, which led to a 35% increase in its stock price, showcasing its strong market performance and growth potential.
See More
AstraZeneca's Drug Trial Shows Promising Results
- Drug Trial Success: AstraZeneca's experimental drug tozorakimab significantly reduced flare-ups in chronic obstructive pulmonary disease cases, leading to a 3% stock increase, with full results expected at an upcoming medical meeting, potentially enhancing the company's competitive edge in respiratory medications.
- Travel Platform Upgrade: Tripadvisor's stock rose 3% after Bank of America upgraded its rating from neutral to buy, citing accelerating activist engagement and rising strategic optionality across its portfolio, reflecting market confidence in its future growth prospects.
- Construction Firm Earnings Beat: Argan's stock surged over 10.5% after reporting fourth-quarter earnings of $3.47 per share and revenue of $262.1 million, both exceeding analyst expectations, indicating strong performance in the construction sector that may attract more investor interest.
- Game Development Platform Forecast: Unity Software's stock jumped over 11% after issuing preliminary first-quarter adjusted EBITDA guidance of $130 million to $135 million, surpassing previous guidance of $105 million to $110 million, suggesting ongoing growth potential in the game development industry.
See More
Novartis Plans $2 Billion Acquisition of Excellergy for Allergy Treatment
- Acquisition Strategy: Novartis is planning to acquire U.S.-based biotech Excellergy for up to $2 billion, aiming to enhance its allergy drug portfolio by introducing the early-stage candidate Exl-111, which is expected to outperform existing market treatments in speed and efficacy.
- Patent Expiration Response: This acquisition represents Novartis' latest bolt-on deal to counteract looming patent expirations, particularly as its best-selling drugs face generic competition, which is anticipated to positively impact future revenue streams.
- Recent Transaction Activity: Prior to the Excellergy deal, Novartis announced the acquisition of Pikavation Therapeutics for up to $3 billion to secure rights to an experimental breast cancer drug, highlighting its strategic focus on oncology.
- Market Reaction: While Novartis shares traded sideways in morning trading in Zurich, they have increased by 33% over the past year, reflecting market confidence in its acquisition strategy and future growth potential.
See More
Gilead to Acquire Ouro Medicines for $2.18B, Expanding Inflammation Pipeline
- Acquisition Details: Gilead Sciences plans to acquire Ouro Medicines for approximately $2.18 billion, which includes $1.68 billion in cash and up to $500 million in contingent milestone payments, significantly enhancing its inflammation drug pipeline.
- R&D Collaboration Potential: Gilead's partnership with Galapagos NV will allow both companies to share trial costs, with Galapagos funding half of the upfront payment and milestone obligations, further advancing research in autoimmune diseases.
- New Drug Prospects: The acquisition will provide Gilead with gamgertamig, a drug showing efficacy in severe antibody-mediated orphan diseases in ongoing Phase 1/2 studies, expected to enter late-stage studies by 2027, indicating strong market potential.
- Market Strategy Expansion: Gilead's CMO stated that this acquisition is a crucial step in expanding treatment options for autoimmune diseases, likely enhancing its competitive position in the biopharmaceutical market while retaining most global commercialization rights and paying royalties of 20% to 23%.
See More
Galapagos Enters Binding Agreement with Gilead for Acquisition
- Acquisition Agreement Details: Under the binding framework agreement with Gilead, Galapagos will receive 50% of the total acquisition consideration, amounting to $1.675 billion in upfront payments and any contingent milestone payments, highlighting its strategic significance in the biotech sector.
- Flexible Capital Utilization: The agreement allows Galapagos to deploy at least $500 million of its cash independently, including up to $150 million for share buybacks, enhancing its capital management flexibility and market confidence.
- Intellectual Property Licensing: The framework includes licenses for certain intellectual property rights related to Ouro's research programs, enabling Galapagos to acquire nearly all of Ouro's operational assets, thereby enriching its product pipeline, particularly in autoimmune disease projects.
- Potential Milestone Earnings: Galapagos is eligible for up to $100 million in milestone payments upon Gilead's initiation of registrational trials for gamgertamig, and will receive tiered royalties of 20-23% on net sales post-commercialization, indicating significant future revenue growth potential.
See More
Galapagos Enters Binding Agreement with Gilead for Ouro Medicines Acquisition
- Acquisition Agreement Details: Galapagos NV has entered into a binding agreement with Gilead Sciences, which will acquire all equity interests of Ouro Medicines for $1.675 billion, allowing Galapagos to secure 50% of the upfront consideration and milestone payments, ensuring sufficient funds for future strategic transactions.
- Product Development Progress: Gamgertamig, a clinical-stage T cell engager, has received Fast Track and Orphan Drug Designation from the FDA and is expected to enter registrational studies by 2027, highlighting its potential in treating autoimmune diseases.
- Cost Sharing Arrangement: Under the agreement, Galapagos will bear all pre-registration development costs for Gamgertamig, including Ouro's clinical trials, while registration-enabling clinical development costs will be shared equally, ensuring effective resource utilization.
- Commercialization Revenue: Gilead will be responsible for the global commercialization of Gamgertamig, with Galapagos entitled to tiered royalties of 20-23% on net sales, which is expected to generate substantial long-term revenue and enhance its market position.
See More
Entergy Partners with Meta, Stock Surges Over 8%
- Entergy Stock Surge: Entergy's stock jumped over 8% after announcing a partnership with Meta, which is expected to save Louisiana customers approximately $2 billion over 20 years, significantly enhancing the company's competitive position in the energy market.
- Carnival Lowers Profit Guidance: Carnival revised its full-year adjusted profit forecast down to about $2.21 per share from $2.48, resulting in a more than 3% drop in its stock price and causing peers like Norwegian Cruise Line and Royal Caribbean to experience similar declines.
- Meta Stock Decline: Meta's shares fell over 3% due to losing two pivotal court cases and announcing layoffs, leading to an 11% drop over the week, highlighting the legal and operational challenges the company is currently facing.
- Argan Exceeds Earnings Expectations: Argan reported fourth-quarter earnings of $3.47 per share on revenue of $262.1 million, surpassing analyst expectations, which led to a 35% increase in its stock price, showcasing its strong market performance and growth potential.
See More
AstraZeneca's Drug Trial Shows Promising Results
- Drug Trial Success: AstraZeneca's experimental drug tozorakimab significantly reduced flare-ups in chronic obstructive pulmonary disease cases, leading to a 3% stock increase, with full results expected at an upcoming medical meeting, potentially enhancing the company's competitive edge in respiratory medications.
- Travel Platform Upgrade: Tripadvisor's stock rose 3% after Bank of America upgraded its rating from neutral to buy, citing accelerating activist engagement and rising strategic optionality across its portfolio, reflecting market confidence in its future growth prospects.
- Construction Firm Earnings Beat: Argan's stock surged over 10.5% after reporting fourth-quarter earnings of $3.47 per share and revenue of $262.1 million, both exceeding analyst expectations, indicating strong performance in the construction sector that may attract more investor interest.
- Game Development Platform Forecast: Unity Software's stock jumped over 11% after issuing preliminary first-quarter adjusted EBITDA guidance of $130 million to $135 million, surpassing previous guidance of $105 million to $110 million, suggesting ongoing growth potential in the game development industry.
See More
Novartis Plans $2 Billion Acquisition of Excellergy for Allergy Treatment
- Acquisition Strategy: Novartis is planning to acquire U.S.-based biotech Excellergy for up to $2 billion, aiming to enhance its allergy drug portfolio by introducing the early-stage candidate Exl-111, which is expected to outperform existing market treatments in speed and efficacy.
- Patent Expiration Response: This acquisition represents Novartis' latest bolt-on deal to counteract looming patent expirations, particularly as its best-selling drugs face generic competition, which is anticipated to positively impact future revenue streams.
- Recent Transaction Activity: Prior to the Excellergy deal, Novartis announced the acquisition of Pikavation Therapeutics for up to $3 billion to secure rights to an experimental breast cancer drug, highlighting its strategic focus on oncology.
- Market Reaction: While Novartis shares traded sideways in morning trading in Zurich, they have increased by 33% over the past year, reflecting market confidence in its acquisition strategy and future growth potential.
See More
Gilead to Acquire Ouro Medicines for $2.18B, Expanding Inflammation Pipeline
- Acquisition Details: Gilead Sciences plans to acquire Ouro Medicines for approximately $2.18 billion, which includes $1.68 billion in cash and up to $500 million in contingent milestone payments, significantly enhancing its inflammation drug pipeline.
- R&D Collaboration Potential: Gilead's partnership with Galapagos NV will allow both companies to share trial costs, with Galapagos funding half of the upfront payment and milestone obligations, further advancing research in autoimmune diseases.
- New Drug Prospects: The acquisition will provide Gilead with gamgertamig, a drug showing efficacy in severe antibody-mediated orphan diseases in ongoing Phase 1/2 studies, expected to enter late-stage studies by 2027, indicating strong market potential.
- Market Strategy Expansion: Gilead's CMO stated that this acquisition is a crucial step in expanding treatment options for autoimmune diseases, likely enhancing its competitive position in the biopharmaceutical market while retaining most global commercialization rights and paying royalties of 20% to 23%.
See More
